Comparative Study
Epub 2006 Apr 19.
A comparison of donor lymphocyte infusions or imatinib mesylate for patients with chronic myelogenous leukemia who have relapsed after allogeneic stem cell transplantation
Affiliations
- PMID: 16627251
Item in Clipboard
Comparative Study
A comparison of donor lymphocyte infusions or imatinib mesylate for patients with chronic myelogenous leukemia who have relapsed after allogeneic stem cell transplantation
Haematologica.
2006 May.
Abstract
Imatinib mesylate is highly effective in relapsed chronic myelogenous leukemia (CML) after allogeneic hematopoetic stem cell transplantation (HSCT). However, it is unknown whether imatinib produces durable molecular remissions. The outcome of CML patients transplanted at our center who had received only imatinib for relapse after HSCT was compared with that of patients treated with donor lymphocyte infusions (DLI). Imatinib therapy resulted in a higher incidence of relapse and inferior leukemia-free survival (p=0.006 and p=0.016, respectively). These data suggest that imatinib alone probably does not cure relapse after HSCT.
Similar articles
-
Extended follow-up of patients treated with imatinib mesylate (gleevec) for chronic myelogenous leukemia relapse after allogeneic transplantation: durable cytogenetic remission and conversion to complete donor chimerism without graft-versus-host disease.Clin Cancer Res. 2004 Aug 1;10(15):5065-71. doi: 10.1158/1078-0432.CCR-03-0580. Clin Cancer Res. 2004. PMID: 15297408
-
Sustained complete molecular remissions after treatment with imatinib-mesylate in patients with failure after allogeneic stem cell transplantation for chronic myelogenous leukemia: results of a prospective phase II open-label multicenter study.J Clin Oncol. 2005 Oct 20;23(30):7583-93. doi: 10.1200/JCO.2005.01.3110. J Clin Oncol. 2005. PMID: 16234522 Clinical Trial.
-
Comparison between patients with Philadelphia-positive chronic phase chronic myeloid leukemia who obtained a complete cytogenetic response within 1 year of imatinib therapy and those who achieved such a response after 12 months of treatment.J Clin Oncol. 2006 Jan 20;24(3):454-9. doi: 10.1200/JCO.2005.03.2011. J Clin Oncol. 2006. PMID: 16421422
-
[Imatinib therapy for patients with chronic myelogenous leukemia].Gan To Kagaku Ryoho. 2005 Mar;32(3):297-303. Gan To Kagaku Ryoho. 2005. PMID: 15791812 Review. Japanese.
-
Treatment of CML in pediatric patients: should imatinib mesylate (STI-571, Gleevec) or allogeneic hematopoietic cell transplant be front-line therapy?Pediatr Blood Cancer. 2004 Oct;43(5):523-33. doi: 10.1002/pbc.20062. Pediatr Blood Cancer. 2004. PMID: 15382266 Review.
Cited by
-
The graft versus leukemia effect: donor lymphocyte infusions and cellular therapy.Front Immunol. 2024 Mar 15;15:1328858. doi: 10.3389/fimmu.2024.1328858. eCollection 2024. Front Immunol. 2024. PMID: 38558819 Free PMC article. Review.
-
Management of Elderly Patients with Newly Diagnosed Chronic Myeloid Leukemia in the Accelerated or Blastic Phase.Drugs Aging. 2016 May;33(5):335-45. doi: 10.1007/s40266-016-0351-8. Drugs Aging. 2016. PMID: 26961697 Review.
-
Allogeneic stem cell transplantation with alemtuzumab-based conditioning for patients with advanced chronic myelogenous leukemia.Leuk Lymphoma. 2009 Jan;50(1):85-91. doi: 10.1080/10428190802626624. Leuk Lymphoma. 2009. PMID: 19142796 Free PMC article.
-
Imatinib impairs CD8+ T lymphocytes specifically directed against the leukemia-associated antigen RHAMM/CD168 in vitro.Cancer Immunol Immunother. 2007 Jun;56(6):849-61. doi: 10.1007/s00262-006-0232-9. Epub 2006 Sep 29. Cancer Immunol Immunother. 2007. PMID: 17009043 Free PMC article.
-
Donor lymphocyte infusions: An experience from a tertiary care center of North India.Asian J Transfus Sci. 2024 Jan-Jun;18(1):124-127. doi: 10.4103/ajts.ajts_211_23. Epub 2024 Jun 21. Asian J Transfus Sci. 2024. PMID: 39036678 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical